NCT03451162View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

July 16, 2021

Study Completion Date

July 16, 2021

Conditions
Breast Cancer
Interventions
DRUG

DHES0815A

DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.

Trial Locations (5)

11101

Memorial Sloan Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

06520

Yale Cancer Center, New Haven

02215

Dana Farber Cancer Institute, Boston

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY